PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...
Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
PTC Therapeutics signs up to $2.9 billion licensing deal with Novartis
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...
Business Insider14h
PTC Therapeutics price target raised to $32 from $26 at Citi
Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, which ...
FierceBiotech2d
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
6 Analysts Assess PTC: What You Need To Know
Throughout the last three months, 6 analysts have evaluated PTC PTC, offering a diverse set of opinions from bullish to ...
Investor's Business Daily on MSN4h
PTC Getting Closer To Key Technical Benchmark
Rating, from 69 to 73.Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen Of The DayThis ...
PTC Therapeutics stock jumps on $2.9B license deal with Novartis for Huntington's disease drug candidate
PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...
PTC (NASDAQ:PTC) Price Target Raised to $210.00
PTC (NASDAQ:PTC – Free Report) had its price objective upped by JPMorgan Chase & Co. from $200.00 to $210.00 in a report ...
MM&M2d
Novartis signs licensing deal worth up to $2.9B with PTC Therapeutics
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
STAT2d
Novartis to pay $1 billion upfront to license Huntington’s drug from PTC
Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...